Intra-intestinal Levodopa Gel for Parkinson's Motor Fluctuations
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neurodegenerative disorders like Parkinson's disease, particularly those involving dopamine replacement therapies, face challenges such as unpredictable absorption, short half-life of levodopa, and fluctuations in dopamine levels, leading to motor fluctuations and dyskinesias.
Innovation Solution
A pharmaceutical gel composition for intra-intestinal administration combining levodopa, a dopamine decarboxylase inhibitor (e.g., carbidopa), and a catechol-O-methyltransferase (COMT) inhibitor (e.g., entacapone), which provides sustained release and improved stability, reducing exposure to metabolic precursors while maintaining therapeutic benefits.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If levodopa is administered orally, then it can cross the blood-brain barrier and be converted to dopamine, but it has short half-life and unpredictable absorption leading to motor fluctuations
Solution Approach 1:
The patent combines levodopa with a dopamine decarboxylase inhibitor (DDI) and a COMT inhibitor in a single pharmaceutical gel composition for intra-intestinal administration. This merging of multiple agents into one formulation addresses the short half-life and unpredictable absorption of levodopa by providing complementary mechanisms: the DDI prevents peripheral conversion to dopamine, while the COMT inhibitor blocks metabolic degradation, thereby extending levodopa's effective half-life and stabilizing dopamine levels in the brain.
Solution Approach 2:
The patent transitions from oral administration to intra-intestinal gel administration, changing the route of delivery from the gastrointestinal tract to direct intestinal infusion. This dimensional change in administration approach bypasses the unpredictable gastric emptying and first-pass metabolism associated with oral tablets, providing more reliable and sustained delivery of levodopa to the absorption site.
2Reliability
If levodopa is administered in high doses to maintain therapeutic benefit, then dopamine replacement is improved, but exposure to metabolic precursors increases causing harmful side effects
Solution Approach 1:
The patent introduces a COMT inhibitor as an intermediary agent that blocks the metabolic pathway of levodopa degradation. This intermediary prevents the formation of harmful metabolic precursors and byproducts while allowing levodopa to maintain its therapeutic conversion to dopamine in the brain, thereby reducing harmful side effects without compromising therapeutic benefit.
Solution Approach 2:
The patent changes the pharmacokinetic parameters of levodopa administration by combining it with metabolic inhibitors, which alters the metabolism and elimination rate of levodopa. This parameter change extends the effective half-life of levodopa, allowing lower doses to achieve the same therapeutic benefit, thereby reducing exposure to harmful metabolic precursors.
3Ease of manufacture
If traditional oral formulations are used, then administration is simple, but shelf life is short and stability is poor
Solution Approach 1:
The patent changes the physical state of the pharmaceutical formulation from dry oral tablets to a liquid gel composition for intra-intestinal administration. This parameter change in formulation state improves stability and extends shelf life by preventing degradation that occurs in solid oral formulations, while the gel matrix provides controlled release properties that maintain therapeutic levels.
Solution Approach 2:
The patent uses a composite gel formulation containing levodopa, DDI, and COMT inhibitor suspended in a gel matrix. This composite material structure provides enhanced stability compared to traditional oral formulations, protecting the active ingredients from degradation while maintaining ease of administration through pump-based delivery systems.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combination achieves stable plasma drug levels, reduces motor fluctuations, and extends shelf life, offering a more effective and stable treatment for Parkinson's disease compared to traditional oral formulations.
Implementation Method 1
dopamine is formed by decarboxylation of the precursor levodopa (L-dopa; L-3,4-dihydroxyphenylalanine) through the enzyme aromatic L-amino acid decarboxylase (also known as DOPA decarboxylase (DDC))
Implementation Method 2
A pharmaceutical gel composition for intra-intestinal administration combining levodopa, a dopamine decarboxylase inhibitor (e.g., carbidopa), and a catechol-O-methyltransferase (COMT) inhibitor (e.g., entacapone), which provides sustained release and improved stability
Data Source
AI summary
The invention relates to a method of treating a dopamine related disorder in a subject, the method comprises the steps of administering therapy to a subject, the therapy comprising a plurality of doses of levodopa over a selected time period, in combination with a dopamine decarboxylase inhibitor (DDI) and a catechol-O-methyltransferase (COMT) inhibitor, wherein: (i) the dose of levodopa is lower; (ii) the dose of DDI is lower; (iii) the dosing of levodopa is less frequent; and/or (iv) the dosing of DDI is less frequent As compared with a reference regimen over the selected time period.